# Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma

> **NCT03927274** · EARLY_PHASE1 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 3 (actual)

## Conditions studied

- Glioma of Brain

## Interventions

- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT03927274
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-20
- **Primary completion:** 2023-05-24
- **Final completion:** 2023-05-24
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Funding unavailable
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03927274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03927274, "Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03927274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*